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Abstract
Venous thromboembolism (VTE) is a common complication of malignancies and epidemiological studies suggest
that lung cancer belonged to the group of malignancies with the highest incidence rates of VTE. Risk factors for
VTE in lung cancer patients are adenocarcinoma, NSCLC in comparison with SCLC, advanced disease,
pneumonectomy, chemotherapy including antiangiogenic therapy. Other risk factors are pretreatment platelet
counts and increased release of TF-positive microparticles. Elevated D-dimer levels do not necessarily indicate an
increased risk of VTE but have been shown to be predictive for a worse clinical outcome in lung cancer patients.
Mechanisms responsible for the increase in venous thrombosis in patients with lung cancer are not understood.
Currently no biomarker is recognized as a predictor for VTE in lung cancer patients.
Although several clinical trials have reported the efficacy of antithrombotic prophylaxis in patients with lung cancer
who are receiving chemotherapy, further trials are needed to assess the clinical benefit since these patients are at
an increased risk of developing a thromboembolism.
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Introduction
Thromboembolism is a well recognized complication of
malignant disease and it is known that cancer patients
have a higher incidence of venous thromboembolism
(VTE), including pulmonary embolism (PE) and deep
venous thrombosis (DVT), compared to the general
population [1].
The incidence of thromboembolic disease in general
population is relatively low, about 1–3 per 1.000 per year
[2] while among cancer patients, the occurrence of VTE
is 4–7 times higher, depending on the type and the stage
of cancer [3].
It is estimated that cancer is responsible for 20 % of all
cases of incident VTE [4].
Epidemiological studies suggest that lung cancer
belonged to the group of malignancies with the high-
est incidence rates [5–9] of VTE.
The association between VTE and lung cancer has
been reported more than 20 years ago [10, 11].
Lung cancer is the leading cause of cancer death in the
United States for both men and women, with over
156,000 deaths in 2011 in the United States [9]. It is also
one of the malignancies that are commonly associated
with VTE, including PE, with reported incidence of VTE
3–13.8 % and that of PE up to 3.8 % [9, 12, 13].
In recent years, there has been increasing attention to
the phenomenon of VTE in lung cancer patients and
several studies have been made to better characterize it.
Review
Epidemiology of lung cancer-associated thrombosis
It is recognized that patients with lung cancer are at risk
for development of VTE. The incidence of VTE in lung
cancer patients has been described in several studies.
Chew et al. [14] investgated the incidence of VTE and
the risk factors associated with development of VTE in a
large popuation-based study of patients with non small
cell (NSCLC) and small cell lung cancer (SCLC). Among
91.933 patients with newly diagnosed lung cancer, the 1-
year and 2-year cumulative VTE incidence were 3.0 and
3.4 %, respectively, with a person-time rate of 7.2 events/
100 patient-years during the first 6 months [14].
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In a retrsospective analysis of a lung cancer cohort of
6732 patienst (control cohort had 17,284 patients), VTE
occurred in 13,9 % of the lung cancer cohort and 1,4 %
of the control cohort [15].
In another retrospective study of 1940 patients with
diagnosis of lung cancer, thromboembolic events were
documented in 9.8 % cases, venous thromboembolic
complications in 78 %, arterial thromboembolic compli-
cations in 27 % cases. About venous thromboembolic
complications, it was documented deep venous throm-
bosis in 55 % cases and pulmonary embolism in 66 %
cases [16].
Recently Zhang et al. [17] described the high preva-
lence of VTE in patients with newly diagnosed lun can-
cer. VTE events occurred in 89 (13,2 %) of the 673
patients enrolled in the study. Forty-two (6.2 %) patients
developed lower extremity deep vein thrombosis (DVT)
alone, 33 (4.9 %) patients developed pulmonary embol-
ism (PE) and 14 (2,1 %) patients developed bth DVT and
PE [17].
The incidence of thrombotic event was evaluated in a
group of 950 patients with lung cancer by Kadlec et al.
[18]. 91 (8,4 %) thromboembolic events were observed
(34 cases of pulmonary embolism, 58 cases of deep ven-
ous thrombosis and 13 cases with simultaneous occur-
rence of both disease) [18]. The most common sources
of venous thrombosis were low limbs (49,74 %) and su-
perior vena cava (5,11 %); less frequent was thrombosis
associated with implantable ports and venous catheters
(3,6 %) [18].
In a retrospective review of lung cancer patients
Alexander et al. reported that the incidence of thrombo-
embolism was 10.8 % after a medin follow up of
10 months [19].
An unclear proportion of VTE events in lung cancer
patients is incidentally discovered.
White et al. [20] identified incident VTE events within
1 year before the cancer diagnosis date, by using registry
data. Among 528 693 cancer cases, the incidence of pre-
ceding VTE was increased over that expected in the year
preceding the diagnosis of cancer, but in particular only
during the 4-month period immediately preceding tha
cancer diagnosis date (p <0.001). Almost all of these un-
expected VTE cases were significantly associated with a
diagnosis of metastatic-stage cancer [20].
In a more recent study, it was observed among 207
subjects with lung cancer that one-third of VTE events
was incidentally discovered [21].
Calleias et al. [22] have evaluated the prevalence of inci-
dental VTE detected by PET-CT among cancer patients in
a retrospective study. The prevalence of incidental VTE
detected by PET-CT was 1.4 % [22]. Patients with genito-
urinary malignancies, colorectal cancer and lung cancer
had the highest rates of incidental VTE at PET-CT [22].
Pathogenesis of VTE in cancer: evidences for lung
cancer
Mechanisms responsible for the increase in venous
thrombosis in patients with cancer are not understood.
Rather than one unifying mechanism, the etiology is
likely multifactorial with different factors assuming
lesser or greater degrees of importance depending on
the clinical setting.
Over the years, researchers have investigated intrinsic
properties of tumor cells that lead to a prothrombotic
state. It is recognized that tumors shed membrane parti-
cles that contain procoagulant activity including tissue
factor and membrane lipids that propogate the coagula-
tion response [23, 24].
Several studies have focused on the role of Tissue Fac-
tor (TF) in the pathophysiology of cancer associated
thrombosis.
Tissue factor (TF) is the physiologic initiator of coagu-
lation and is commonly expressed in a variety of malig-
nancies [25, 26]. Overexpression of TF in tumor cells or
elevated TF levels in association with microparticles in
the systemic circulation may contribute to systemic hy-
percoagulability [27]. Tumor cells express TF and spon-
taneously release TF-positive microparticles (MPs) into
the blood. MPs are small membrane vesicles that are
highly procoagulant. Several studies have shown that in-
creased levels of TF-positive MPs correlate with venous
thrombosis in patients with cancer.
In the past, some studies demonstrated the expression
of TF by lung cancer cells [28, 29].
Sawada et al. [30] have previously demonstrated in-
creased TF expression in malignant cells from patients
with lung cancer. Remarkably, in their study, TF expression
levels correlated with the presence of metastatic tumors.
Goldin-Lang et al. [31] also demonstrated increased TF ex-
pression in NSCLC, although no direct correlation be-
tween disease stage and TF expression levels was detected.
More recently the expression TF protein and/or
mRNA have been documented in malignant cells or tis-
sue in NSCLC [32].
Sato et al. [33] described a case of Trousseau’s syn-
drome that shows the possible contribution of TF in the
pathogenesis of DVT/PE in patients with lung cancer.
They observed a marked increase in plasma TF level, to-
gether with positive staining of cancer cells with mono-
clonal anti-TF antibody. Therefore tissue factor (TF)
originating from lung adenocarcinoma appeared respon-
sible for recurrent deep vein thrombosis (DVT) and pul-
monary thromboembolism (PE) [33].
Similarly, Del Conde et al. [34] reported a higher
level of plasma TF in a patient with a giant-cell lung
carcinoma with a severe form of Trousseau’s syn-
drome. In this case was observed a 41-fold higher
concentration of plasma TF as compared with the
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mean plasma TF concentration examined in 16 normal
individuals [34].
Risk factors of VTE in patients with lung cancer
Cancer increases the risk of thromboembolic events.
Risk factors, such as age, gender, bed-rest, venous cathe-
ters, surgery, chemotherapy with or without adjuvant
hormone therapy, radiotherapy and infections, also in-
crease the risk of thrombosis in cancer patients.
Rates of VTE vary substantially between cancer patients,
considerably depending on clinical factors, the most im-
portant being tumor type and stage.
In this review we have focused on studies which investi-
gated factors could be identified as predictors of vascular
events in lung cancer and their prognostic significance.
Haemostatic parameters
Thrombocytosis can result in thrombosis and is fre-
quently observed in patients with malignancies The
mechanism underlying development of thrombocytosis
in lung cancer patients remains unclear; one of possible
mechanisms might be tumor-associated elevation of
bone marrow-stimulating cytokines such as interleukin
(IL)-6, IL-1 and macrophage colony stimulating factor
(M-CSF). These cytokines could exhibit thrombocytosis.
Incidence and prognostic significance of thrombocytosis
in patients with lung cancer has been investgated in
some studies [35].
Pedersen and Milman [36] examined data on platelet
counts obtained in a large population (1178 patients) of
patients with primary lung cancer. A high prevalence
(32 %) of elevated platelet counts was observed in pa-
tients with lung cancer. The frequency of thrombo-
embolism in patients with thrombocytosis was not
statistically different from the frequency found in pa-
tients with normal platelet counts so, according the au-
thors, thrombocytosis should not be considered as a risk
factor predisposing to thromboembolism in cancer pa-
tients [36]. Thrombocytosis was associated with the
tumour load according to the disease stage. Surgical
debulking of the tumour resulted in significantly reduced
platelet counts. Respect to survival, patients with throm-
bocytosis had a significantly poorer survival than pa-
tients with normal platelet counts. According to the
results of this study, thrombocytosis is an indipendent
prognostic factor of survival in patients with primary
lung cancer [36].
Tomita et al. [35] evaluated the prognostic effect of
thrombocytosis in patients with resectable NSCLC. 240
consecutive NSCLC patients, who received surgical re-
section, were reviewed retrospectively and the survival
impact of preoperative platelet count was investigated.
The 5-year survival of patients with and without throm-
bocytosis was 28,87 and 63,73 %, respectively (p <
0.0001). Therefore preoperative platelet count was a
prognostic factor for resectable NSCLC patients [35].
These findings are supported by a more recent study
[37] that assessed the prognostic value of thrombocyto-
sis and its relation with patients undergoing surgery for
lung cancer. Thrombocytosis appeared most frequently
in patients with squamous cell lung cancer and among
smokers. The presence of perioperative thrombocytosis
in patients undergoing surgery had a negative prognostic
value (the overall 5-year survival was worse in patients
with thrombocytosis (p < 0,001) [37].
Recently Kadlec et al. [18] observed in a large cohort
of lung cancer that patients with thromboembolic events
showed significantly higher levels of platelet count at the
time of diagnosis of lung cancer and a platelet count
above 330.5 × 109 was associated with OR for major
thromboembolic events was 3.66 (2.25–5.96) — a statis-
tically significant value. Thrombocytosis was found in
patients with advance disease, more commonly in men,
with no apparent correlation with the clinical stage of
the disease [38].
On the contrary, Demirci et al. in a restrospective
study of consecutive 281 patients with lung cancer did
not observe a significant correlation between vascular
events and thrombocytosis [39].
Plasma levels of D-dimer are elevated in cancer pa-
tients. Activation of the extrinsic coagulation system and
the fibrinolytic cascade within a tumour is thought to be
related with growth, invasion and metastasis. Although
high D-dimer was described as a predictor of VTE in
earlier works, it is now recognized that it does not ne-
cessarily indicate an increased risk of VTE in cancer pa-
tients [18].
Several studies have demonstrated that elevated D-
dimer levels are associated with a poor prognosis in
cancer patients. In patients with both non-small cell
and small cell lung cancer, increased plasma D-dimer
levels were shown to be predictive for a worse clinical
outcome [40].
In addition in cancer lung patients it has been shown
that D-Dimer plasma levels decrease or increase after re-
sponse and progressive disease, respectively, and can act
as a predictive factor of the evolution of the disease [41].
Recently Ferroni et al. [42] hypothesized that the use of
a novel high-sensitive D-dimer determination could pre-
dict chemotherapy associated VTE in lung cancer patients
with intermediate risk, according to Khorana’s assesment
model [43]. Overall 108 lung cancer patients at the start of
a new platinum-based chemotherapy were evaluated. A
cutoff level of 1500 was obtained by statistical analysis; it
resulted in a sensitivity of 81 %, a specificity of 69 %, a
positive predictive value of 31 %, a negative predictive
value of 96 % and an accuracy of 70 %. Patients with HS-
D-dimer levels above the cutoff had a worse VTE- free
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survival (60 %) compared with those with levels below the
cut-off (95 %, p = 0.0001) [42]. The use of High Sensitive
D-dimer determination prior to chemotherapy may help
to identify cancer patients with an intermediate risk of
VTE who could benefit from thromboprophylaxis [42].
With regard to other hemostatic factors, there are dif-
ferent results in the literature.
Gabazza et al. [11] found significantly higher levels of
thrombin-antithrombin complexes III, D-dimer, and
plasmin-alpha 1-antiplasmin complexes in lung cancer
patients, suggesting an increased activation of coagula-
tion and fibrinolysis.
In a prospective study Zecchina et al. [44] investigated
the activation of the hemostatic factors in 45 patients
undergoing chemotherapy for lung cancer. They reported
no significant changes in such parameters as D-dimer, fi-
brinogen, and activated protein C, however found a sig-
nificant increase in platelet count 21 days after the
administration of chemotherapy, correlating with the oc-
currence of VTE.
Elevated levels of procoagulant factors, such as lupus
anticoagulant, anticardiolipin antibodies to factor VIII,
and certain cytokines such as interleukin-6 and tumor ne-
crosis factor, have also been identified as increased risk
factors for VTE in patients with lung cancer [28, 29].
Recently Kadlec et al. in a study population of 950
lung cancer patients did not find significantly higher me-
dians of coagulation parameters (D-dimer, fibrinogen,
thrombin time and aPTT) [18].
Hystological types of lung cancer
Over the years several studies investigated the VTE risk
in different hystological types of lung cancer.
In the past, autopsy and retrospective studies indicated
that various adenocarcinomas are most strongly associ-
ated with VTE [45, 46]. This has led to the widespread
belief that mucin-producing adenocarcinomas are in-
deed the most common tumours associated with VTE.
This notion was supported by the findings of several
other studies [14, 15, 47]. Blom et al. [47] investigated
thrombotic risk in 537 NSCLC patients and observed
that the risk of VTE was 20-fold higher than in the gen-
eral population (standardized morbidity ratio: 20.0
(14.6–27.4). Patients with adenocarcinoma of the lung
had three-fold higher risk (incidence 66.7 per 1000 years)
than patients with squamous cell carcinoma of the lung
(incidence: 21.2 per 1000 years). In adeno and squamous
carcinoma together, they observed 39 VTE events over
879 years of follow up for an overall incidence of VTE of
44.4 per 1000 person years [47].
In a restrospective analisys of a large cohort of patients
with NSCLC and SCLC, was observed that adenocarcin-
oma histology (HR = 1.9 vs. squamous cell, 95 % CI =
1.7–2.1) and advancing cancer stage (HR = 4.0 for
metastatic vs. local disease, 95 % CI = 3.4–4.6) were sig-
nificant predictors of developing VTE within 1 years of
NSCLC diagnosis [14].
Recently Kadlec et al. and Lee [18, 48] identified
adenocarcinoma histology as a risk factor for develop-
ment of VTE.
Tagalakis et al. [13] described a high incidence
(13,6 %) of deep vein thrombisis in a cohort of 493 pa-
tients with NSCLC.
In a retrospective analysis of lung cancer patients,
Alexander et al. [19] observed, that thromboembolism oc-
curred equally in patients with non-small cell and small
cell lung cancer (10.8 and 10.5 % respectively), and more
frequently among patients with adenocarcinoma com-
pared to squamous cell carcinoma (14.7 and 5.3 % respect-
ively) [19].
Differently not a significant correlation between vascu-
lar events and histological type, or TNM stage was ob-
served in a retrospective study by Demirci et al. [39].
VTE was a significant predictor of death within 2 years
for both NSCLC and SCLC, HR = 2.3, 95 % CI = 2.2–2.4,
and HR = 1.5, 95 % CI = 1.3–1.7, respectively [14].
Cancer therapy
Cancer therapy itself has been shown to increase the risk
of VTE, whether it be chemotherapy, antiangiogenic
therapy, or hormonal therapy.
Combined chemotherapy (in combination with radio-
therapy) is the current standard treatment for advanced
stage NSCLC as well as in the treatment of SCLC pa-
tients and VTE is a well known complication of antican-
cer therapy [49, 50].
How chemiotherapy contributes to VTE risk has not to
our knowledge been elucidated completely but likely in-
volves a combination of direct endothelial damage and
down regolation of endogenous anticoagulants [51].
In an observational study by Blom et al. [47], the overall
incidence of VTE in an ambulatory population with lung
cancer starting a new chemotherapy was 1.93 % over a me-
dian follow up period of 2.4 months. The rate of VTE ob-
served in this study (0,8 % per month) was substantially in
excess of the estimated rate of approximately 0.04 % per
month for the entire cancer population. The data suggest
that chemotherapy is associated with three-fold increased
risk for VTE over and above this already elevated rate,
with further increases with time on chemotherapy [47].
Khorana et al. [52] analysed data from a prospective
multicentre study in 3003 patients treated with at least
one cycle of chemotherapy. They reported an odds ratio
for VTE of 1.86 % (95 % CI, 0.67-3.38) in lung cancer pa-
tients [52].
The results of this study are supported by Hicks et al.
[53] that have conducted a pooled analysis of three clinical
trials. They observed that the risk of VTE is increased in
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patients with NSCLC at all stages who receive chemother-
apy, but not erlotinib or BMS-275291, whether it is given
as postoperative adjuvant therapy or fort he treatment of
advanced disease [53].
Numico et al. [54] prospectively assessed the occur-
rence of VTE in patients with NSCLC who were treated
consecutively with cis-platin and gemcitabine. They ob-
served 22 VTEs in 19 of 108 stage II-IV NSCLC patients
who underwent chemotherapy (17,6 %; 95 % CI 10.3–
24.8) [54].
Recently a retrospective study of lung cancer patients
showed that chemotherapy-treated patients experienced
thromboembolism more often than patients who did not
receive chemotherapy (HR 5.7 95 % CI 2.2–14.8) [19].
Among lung cancer patients receiving chemotherapy,
it was described that the majority of VTE events occur-
ring within 6 months of initiation of chemotherapy [55].
The presence of a VTE event is significantly associated
with an increased risk of mortality [55].
With regard to antiangiogenic chemotherapy, researchers
have focused on neoangiogenesis inhibition with VEGF in-
hibitor bevacizumab.
While some trials suggested that bevacizumab may be
associated with increased risk for VTE [56], others indi-
cate that bevacizumab is not associated with significant
elevation risk in the context of contemporary chemo-
therapy regimens [57].
Scappaticci et al. [58] conducted a post hoc analysis of
pooled data from randomized controlled trials evaluating
combination treatment with bevacizuamb and chemother-
apy vs chemotherapy alone in 1745 patients with colorec-
tal, breast, or non small cell lung cancer. Compared with
chemotherapy alone, bevacizumab was associated with a
2-fold increase in arterial thromboembolic events (p =
0.031) but was not found to be associated with an in-
creased risk of venous thromboembolic events [58].
These data are in contrast to a recent systematic review
and meta analysis by Nalluri et al. [59]; results indicated
that bevacizumab was associated with an increased risk of
VTE, with a relative risk (RR) of 1.33 (95 % CI, 1.13–1.56,
p < 0.001) compared with controls [59].
Antiangiogenic agents also contribute to thrombosis,
perhaps through endothelial cell and platelet activa-
tion [27].
Postoperative use of angiogenesis drugs EGFR-TKI ap-
plication were high risk factors for VTE in lung cancer
patients [60].
With regard to metalloproteinase inhibitor prinoma-
stat there are divergent data.
According to Behrendt et al. [61], the use of the me-
talloproteinase inhibitor prinomastat in combination
with chemotherapy, but not alone, resulted in approxi-
mately doubling oft he risk of VTE in advanced NSCLC
patients [61].
In contrast to these data in a more recent study the
addition of another metalloproteinase inhibitor BMS-
275291 to chemotherapy in patients with advanced
NSCLC did not increase the risk [53].
The addition of aprinocarsen, a protein kinase C- alfa
antisense oligonucleotide, to standard chemotherapy in
patients with advanced stage NSCLC, significantly in-
creased thromboembolism [62].
Surgery
It is known that patients undergoing surgery for cancer
have a higher risk of postoperative DVT, despite throm-
bosis prophylaxis [63], than those having surgery for non
malignant diseases [64]. Cancer patients have at least
twice the risk of postoperative DVT and are known to
have a more than three-fold increased risk of fatal pul-
monary embolism than non cancer patients undergoing
similare procedures [65].
Among patients who undergo surgical resection due
to oncological processes, VTE is considered a major
cause of mortality and may serve as an important pre-
dictor of survival.
With regard to lung cancer, Ziomek et al. [66] ana-
lyzed 77 patients who underwent lung resection surgery
for lung cancer. They found that 20 patients (26 %) had
a thromboembolic episode in the postoperative period
(15 cases of DVT and 5 cases of PE) [66].
Lyman et al. [67] established that the risk of having a
fatal PE after surgery is three times higher than in pa-
tients undergoing the same surgery for benign causes.
Pneumonectomy has been associated with a higher
risk of VTE than lobectomy for stage I and II lung can-
cer, due to greater activation of coagulation, which ap-
pears from the seventh postoperative day [68].
Mason et al. [69] described a higher incidence (7.4 %)
of postoperative VTE after pneumonectomy for malig-
nancies as compared with that reported in older litera-
ture, with a peak incidence within 7 days after the
operation.
Yang et al. [60] explored clinical risk factors for VTE
in postoperative lung cancer patients. They described
that the highest incidence of VTE is within 1 month
after lung cancer surgery and high risk factors for VTE
include incomplete surgical resection, postoperative use
of anti-angiogenesis drugs, EGFR-TKI application and
an increase in preoperative D-dimer level [60].
Recently Kadlec et al. [18] reported in a study popula-
tion of 950 patients with lung cancer, that patients
undergoing surgery had an incidence of 17.6 % of VTE
(11 and 48.4 % for those undergoing radiotherapy and
chemotherapy, respectively).
Differently Dentali et al. [70] have observed a low
incidence of VTE in lung cancer patients undergoing
surgery procedures. They described, in a series of 693
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patients who underwent thoracotomy for lung cancer
under an antithrombotic prophylaxis protocol, an in-
cidence of VTE and PE of 1.7 and 1.3 %, respectively,
with 0.6 % mortality attributed to PE [70].
Gomez-Hernandez et al. [71] have found a low preva-
lence of VTE in a retrospective study of 6004 patients
undergoing elective thoracic surgery procedures. Among
surgical procedures lobectomy and pneumonectomy were
the most common and lung cancer was the main diagnosis
(2245 cases). The prevalence of VTE was 0,18 % [71]. Ac-
cording to Gomez-Hernandez et al., this low prevalence
may be attributable to the use of thromboprophylaxis pro-
tocols, which include the use of anticoagulant drugs and
mechanical measures (intermittent compression systems
and elastic stockings) and early ambulation [71].
A recent published review by Christensen et al. [72]
analysed 19 studies with a total of 10,660 patients with
primary lung cancer undergoing operations with curative
intent. The mean risk of VTE was estimated at 2.0 %
(range, 0.2–19 %), with a mean observation period of
16 months (range, 0.1–22). The risk of VTE seems to
occur predominantly within the initial postoperative
period, and subsequently the risk falls [72].
With respect to mortality, it was described that pul-
monary embolism is the second cause of mortality after
pneumonectomy for a malignancy and such patients
have the highest risk of dying from pulmonary embolism
[73]. Weder et al. [74] in their series of 176 patients who
underwent pneumonectomy due to lung cancer after
neoadjuvant chemotherapy, described a mortality of 3 %;
half were attributed to pulmonary thromboembolic com-
plications [74].
Interestingly, mortality due to VTE has been reported
to occur predominantly in patients with squamous cell
lung carcinoma following surgery [73].
VTE prophylaxis and treatment in cancer patients:
evidences for lung cancer
In cancer patients the risk of VTE is particularly high in
association with surgery for cancer and chemotherapy.
Haas et al. [75] investigated the efficacy of low-
molecular-weight heparin (certoparin 3000 IU once
daily for 6 months) in the prevention of venous
thromboembolism among ambulatory cancer patients.
In two double blind studies, they analyzed patients
with metastatic breast cancer (TOPIC −1) or patients
with III/IV stage NSCLC (TOPIC-2). A post hoc ana-
lysis showed certoparin significantly reduced VTE in
stage IV lung carcinoma (3.5 % vs 10.2 %; P = .032)
without increased bleeding [75].
Zhang et al. [76] have recently publicated a systematic
review and meta-analysis about the efficacy and safety of
adjunctive anticoagulation in patients with lung cancer
without indication for anticoagulants. The analysis of
2185 patients showed that anticoagulation reduced the
incidence of VTE (RR = 0.55, 95 % CI 0.31–0.97; p = 0.04)
and thromboembolic events (RR = 0.48, 95 % CI 0.28–
0.82; p = 0.008). Furthermore anticoagulation showed
significant improvement in survival at 1 year (RR 1.18,
95 % CI 1.06–1.32; p = 0.004) and at 2 years (RR 1.27,
95 % CI 1.04–1.56; p = 0.02), especially for patients with
SCLC and prolonged life expectancy [76]. Between sub-
cutaneus heparin and vitamin K antagonist, heparin
was associated with a lower risk of bleeding [76].
In a retrospective analysis of lung cancer patients, pa-
tients receiving chemotherapy experienced thrombo-
embolism more often than patients who did not receive
chemotherapy (HR 5.7 95 % CI 2.2–14.8) [19]. Pharmaco-
logical thromboprophylaxis was not routinely or systemat-
ically prescribed for lung cancer outpatients during any
treatment phase [19]. The majority (83 %) of thrombo-
embolic events occurred in the ambulatory care setting. It
was stressed that thromboprophylaxis guidelines should
be developed for the ambulatory care setting [19].
Recently the neutrophil-lymphocyte ratio (NLR) was
identified as a potentially useful marker for predicting
clinical outcome in patients with anticoagulation for
VTE. The study has demonstrated that NLR at the time
of VTE diagnosis could be a useful biomarker for pre-
dicting the response and prognosis following anticoagu-
lation in patients with lung cancer and VTE [77].
The CARMEN study is an interesting french observa-
tional study, in which the researchers evaluated the adhe-
sion to guidelines for treatment of VTE in hospitalized
patients [78].
Among cancer patients, 64 % had metastatic disease.
Cancer sites were gastro-intestinal (25 %), gynecologic
(23 %), pulmonary (21 %), hematological (14 %), urologic
(10 %), or other (8 %) [78].
It was observed that overall adhesion to guidelines
was present in 59 % of patients. During initial treat-
ment, adhesion was high but dropped during the
long-term mantenance. Lung and hematological ma-
lignancies were significantly associated with the high-
est and lowest rates of adhesion [78].
Conversely Alexander et al. [79] made a survey
among clinicians regarding appropriate thrombopro-
phylaxis for patients with lung cancer in order to iden-
tify variation in practice and/or divergence from
evidence-based clinical practice guidelines. Clinicians
consistently identified patients with lung cancer as hav-
ing a high thromboembolic risk in both ambulatory and
surgical settings, but with differences in recommenda-
tions and variation in practice [79].
Conclusions
Venous thromboembolism, including pulmonary embol-
ism and deep venous thrombosis, is a common occurrence
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within the cancer population. Lung cancer is one of the
most common cancer in western countries with reported
high incidence of VTE. VTE in hospitalized lung cancer
patients is associated with longer length of stay, higher in-
patient mortality rates, increased cost and greater disabil-
ity upon discharge compared to other inpatient lung
cancer patients [80]. Risk factors for VTE in lung cancer
patients are adenocarcinoma, NSCLC in comparison with
SCLC, advanced disease, pneumonectomy, chemotherapy
including antiangiogenic therapy. Other risk factors are
pretreatment platelet counts and increased release of TF-
positive microparticles. Elevated D-dimer levels do not ne-
cessarily indicate an increased risk of VTE but have been
shown to be predictive for a worse clinical outcome in
lung cancer patients.
Currently no biomarker is recognized as a predictor
for VTE in lung cancer patients.
Although several clinical trials have reported the efficacy
of antithrombotic prophylaxis in patients with lung cancer
who are receiving chemotherapy, further trials are needed
to assess the clinical benefit since these patients are at an
increased risk of developing a thromboembolism.
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